First Tracks Biotherapeutics (HAM:B43) Interest Coverage: N/A (As of Dec. 2024)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. First Tracks Biotherapeutics's Operating Income for the six months ended in Dec. 2024 was €-172.95 Mil. First Tracks Biotherapeutics's Interest Expense for the six months ended in Dec. 2024 was €0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. First Tracks Biotherapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for First Tracks Biotherapeutics's Interest Coverage or its related term are showing as below:


HAM:B43's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


First Tracks Biotherapeutics  (HAM:B43) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


First Tracks Biotherapeutics Interest Coverage Related Terms


First Tracks Biotherapeutics Interest Coverage Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

First Tracks Biotherapeutics Interest Coverage Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Interest Coverage
N/A N/A

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Interest Coverage N/A N/A

HAM:B43 vs ALT, RGNX, MDXG: Interest Coverage Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


First Tracks Biotherapeutics Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's Interest Coverage falls into.


HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

First Tracks Biotherapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, First Tracks Biotherapeutics's Interest Expense was €0.00 Mil. Its Operating Income was €-172.95 Mil. And its Long-Term Debt & Capital Lease Obligation was €13.48 Mil.

GuruFocus does not calculate First Tracks Biotherapeutics's interest coverage with the available data.

First Tracks Biotherapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, First Tracks Biotherapeutics's Interest Expense was €0.00 Mil. Its Operating Income was €-172.95 Mil. And its Long-Term Debt & Capital Lease Obligation was €13.48 Mil.

GuruFocus does not calculate First Tracks Biotherapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price